ZNF160 is a zinc finger transcription factor that functions as a DNA-binding protein involved in transcriptional regulation 1. Mechanistically, ZNF160 represses gene transcription by interacting with the scaffold protein KAP1 through its N-terminus to recruit histone deacetylase, leading to histone deacetylation and subsequent chr19 silencing 1. In intestinal epithelial cells, ZNF160 suppresses TLR4 gene expression through epigenetic modifications including histone deacetylation and DNA methylation at the TLR4 promoter, thereby maintaining intestinal homeostasis by reducing inflammatory responses to commensal bacteria 1. Clinically, ZNF160 exhibits disease relevance across multiple conditions. Its expression levels are negatively correlated with Parkinson's disease severity, suggesting utility as a blood biomarker for stratifying individuals at risk of PD prior to motor symptom onset 2. In osteoarthritis, ZNF160 is a hub differentially expressed gene associated with immune infiltration, particularly mast cell activation 3. Additionally, ZNF160 methylation status serves as a biomarker for head and neck squamous cell carcinoma detection in primary tissue and saliva with 100% specificity 4, and its expression is associated with chemoradiotherapy response prediction in rectal cancer patients 5. These findings indicate ZNF160's potential as a multi-disease biomarker and therapeutic target.